Company news

Share this article:
Bristol-Myers Squibb Company and Kosan Biosciences have signed a merger agreement providing for the acquisition of Kosan, a cancer therapeutics company. The transaction is valued at $190 million. The acquisition of Kosan will enhance Bristol-Myers Squibb's pipeline with compounds in two important classes of anticancer agents: novel Hsp90 (heat shock protein 90) inhibitors and epothilones, the companies said.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions